Natco Pharma Q3 End results: NATCO Pharma Ltd reported a pointy decline of 37.75 p.c in consolidated web revenue for the December quarter, primarily impacted by a downturn in formulations exports. The corporate’s consolidated web revenue stood at ₹132.4 crore in Q3 FY2025, a drop from ₹212.7 crore recorded within the corresponding quarter of the earlier fiscal yr, in response to a regulatory submitting.
The pharmaceutical agency’s consolidated income from operations fell to ₹474.8 crore in Q3 FY2025, down from ₹758.6 crore within the year-ago interval, reflecting a 37.4 p.c lower in earnings.
The corporate’s earnings earlier than curiosity, taxes, depreciation, and amortization (EBITDA) noticed a drastic decline of 85.5 p.c year-over-year, falling to ₹38.8 crore in Q3 FY2025 from ₹268.1 crore in Q3 FY2024. This steep drop in working earnings led to a major contraction within the EBITDA margin, which plummeted by 2717 foundation factors to eight.2 p.c from 35.3 p.c within the corresponding quarter of the earlier yr. The contraction in margins underscored the challenges confronted by the corporate throughout this era.
Whole bills for the quarter have been recorded at ₹487.4 crore, marking a discount from ₹539.3 crore in the identical interval final yr. Regardless of the decline in bills, the corporate’s general efficiency remained underneath strain attributable to weak income technology.
A key issue behind the earnings hunch was the steep fall in formulation exports, which dropped to ₹285.8 crore in Q3 FY2025 from ₹605.6 crore in Q3 FY2024. In the meantime, home formulation gross sales additionally registered a decline, amounting to ₹96.1 crore in Q3 FY2025 in comparison with ₹99.4 crore within the corresponding interval final yr, as per the corporate’s investor presentation.
Dividend
In a separate improvement, the corporate’s board of administrators, in a gathering held on Wednesday, declared a 3rd interim dividend of ₹1.50 per fairness share of ₹2 every for the monetary yr 2024-25. NATCO Pharma introduced that the report date for figuring out shareholders eligible to obtain the interim dividend has been set for Tuesday, February 18, 2025. The corporate additional said that the cost of the declared interim dividend will begin from February 28, 2025.
